| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Outline of Final Research Achievements |
The effect of pre-treatment with SU5416, a selective VEGF receptor-2 inhibitor, on tumor disposition and in-vivo anti-tumor activity of polyethylene glycol (PEG)-modified liposomal paclitaxel (PL-PTX) was evaluated. To improve the solubility of SU5416, the inhibitor was formulated in PEGylated O/W emulsion (PE-SU5416). Pre-treatment with PE-SU5416 significantly enhanced the in-vivo anti-tumor effect of PL-PTX. The pretreatment with PE-SU5416 improved the tumor vessel functions, including oxygen supply. Furthermore, the pre-treatment with PE-SU5416 increased the distribution of PEG liposomes and included PTX in the core region of the tumor. These results suggest that the functional normalization of the tumor vasculature by the pre-treatment with PE-SU5416 enabled liposomes to reach the deeper regions within tumor tissues, leading to more potent anti-tumor activity of PL-PTX.
|
